SAGE-547 severe postpartum depression shows positive effect
Release date: 2016-07-13 Today, the American biotechnology company Sage Therapeutic's epicondosterone injection SAGE-547 shows efficacy in a second phase of postpartum depression. In this 21-member clinical trial, SAGE-547 quickly relieved depression. Intravenous infusion of 70% of patients with SAGE-547 for 60 hours showed no depressive symptoms, while only 10% of patients in the placebo group were relieved. This effect lasted for at least 30 days. SAGE-547 is well tolerated, especially for the side effects of similar drugs with placebo. Sage shares rose 37% today. Pregnenolone is a positive organ regulator of the GABA receptor type A, which means that when this compound binds to the GABA receptor, it enhances the binding ability of this receptor to GABA (Galmartine), thereby indirectly activating this receptor. . GABA receptors are a class of ion channels that control chloride ions. They can be composed of many different protein plates, so there are many drugs that can regulate such receptors. The most famous one is benzodiazepine. Drugs, alcohol can also regulate such receptors. Abnormal expression of GABA receptors is associated with many diseases, but rational design of GABA modulators is very difficult. Although many drugs have been shown to be GABA receptor modulators after they are marketed, as far as I know, they have not been rationally designed. The GABA receptor is the major inhibitory receptor, and 20-30% of neurons express such receptors, so they function widely. Pregnenolone is an endogenous hormone that regulates the GABA receptor. Hormones have advantages and disadvantages as drugs. On the one hand, hormones are highly optimized ligands, but on the other hand, hormones are mostly localized, released, and eliminated, so systemic side effects are large. The therapeutic window of the pregnenolone does not seem to be large, which may be one of the reasons why the pregnenolone still needs intravenous drip for a half-life of about 4 hours. Pregnenolone has previously failed in clinical trials of severe depression in premenopausal women, and high doses of pregnenolone induce depressive symptoms in postmenopausal women. But postpartum depression seems to be a special type of depression, because hormonal imbalance is one of the causes. There is a certain negative correlation between the concentration of pregnenolone in pregnancy and the degree of depression in pregnancy, so there seems to be a theoretical basis for supplementing the pregnane enolone. However, the pregnenolone has fluctuations with the body's needs, and high concentrations have multiple side effects, so it is more difficult to find safe and effective doses. The efficacy reported today is quite significant and is good news for patients with postpartum depression. It is estimated that 10-15% of women have different degrees of postpartum depression, so it is a big indication, but now the diagnosis and treatment is not enough. However, this trial has only 10 people to take the drug, so whether the effect is true or not is subject to greater trial verification. Another important finding of recent treatment for depression is ketamine. Interestingly, ketamine also requires intravenous drip, and it is not known whether this mode of administration plays a role. The development of depression drugs is known for its high failure rate. SAGE-547 is an endogenous hormone. GABA is a widely expressed and complex receptor. This clinical trial has only a few patients, so the future of this product is still full of uncertainty. This is similar to finding a gold mine in the virgin forest, even if it is found in gold. Source: US and Chinese medicine source Frozen Squid Products,Frozen Squid,Frozen Calamari Rings,Frozen Squid Woolworths Zhoushan Fudan Tourism CO., LTD , https://www.fudanfood.com